Purple Biotech
PPBT
29 hedge funds and large institutions have $5.52M invested in Purple Biotech in 2020 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 4 closing their positions.
450% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 4
164% more funds holding
Funds holding: 11 → 29 (+18)
155% more capital invested
Capital invested by funds: $2.17M → $5.52M (+$3.35M)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0.01% less ownership
Funds ownership: 0.01% → 0% (-0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$177K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$125K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$117K |
| 4 |
ECM
ETrade Capital Management
Arlington,
Virginia
|
+$59.9K |
| 5 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$24.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$605K |
| 2 |
Morgan Stanley
New York
|
-$273K |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$145K |
| 4 |
Renaissance Technologies
New York
|
-$116K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$61.9K |
PPBT Hedge Fund Activity: Q2 2020 in Review
29 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q2 2020, worth a combined $5.52M — up 155% from $2.17M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new PPBT positions and 4 closed out — a net gain of 18 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $177K. The largest seller was CVI Holdings, exiting entirely with an estimated $605K sold.
- 29 institutional investors held Purple Biotech (PPBT) as of Q2 2020, up from 11 in Q1 2020.
- Funds reported $5.52M of Purple Biotech stock for Q2 2020, up 155% quarter-over-quarter.
- 22 funds opened new Purple Biotech positions in Q2 2020 and 4 closed out, a net change of +18 holders.
- The largest Purple Biotech buyer in Q2 2020 was Citadel Advisors, an estimated $177K added.
- The largest Purple Biotech seller in Q2 2020 was CVI Holdings, an estimated $605K sold.
Based on aggregated 13F filings for Q2 2020.